NCT05636904

Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

A Proof-Of-Concept Phase 1b/2a Randomized, Vehicle, and Comparator-Controlled Study of Topical DLQ01 to Assess the Safety and Efficacy in the Treatment of Androgenetic Alopecia (AGA) in Men

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Dermaliq Therapeutics, Inc. · Industry
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in 120 males with Androgenetic Alopecia.

Conditions

• Androgenetic Alopecia

Interventions

Type	Name	Description
DRUG	prostaglandin F2a analogue in vehicle solution high dose	Topical treatment for 24 weeks
DRUG	prostaglandin F2a analogue in vehicle solution low dose	Topical treatment for 24 weeks
DRUG	active ingredient-free vehicle solution to DLQ01	Topical treatment for 24 weeks
DRUG	Minoxidil 5% Topical Solution	Topical treatment for 24 weeks

Timeline

• Start date: 2022-12-05
• Primary completion: 2024-03-28
• Completion: 2024-03-28
• First posted: 2022-12-05
• Last updated: 2024-04-08

Locations

2 sites across 1 country: Australia